Trial Profile
Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms COMPASS
- Sponsors Akebia Therapeutics; Keryx Biopharmaceuticals
- 25 Mar 2021 According to an Akebia Therapeutics media release, data from this trial will be presented at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21),
- 09 Oct 2020 According to an Akebia Therapeutics media release, abstract to be presented at ASN Kidney Week are now available online on the ASN Kidney Week abstract portal.
- 09 Oct 2020 According to an Akebia Therapeutics media release, data from this study will be presented virtually at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week).